BRISBANE, Calif., May 01, 2018 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight the first and only clinically and analytically validated dd-cfDNA test for identifying kidney injury, AlloSure, at the 2018 American Transplant Congress CareDx sponsored Lunch Symposium entitled Innovation in Allograft Health Surveillance: Clinical Implementation of AlloSure Testing for Kidney Transplant Patient. The symposium will be held from 1:00 PM to 2:15 PM Pacific Time on June 5th, 2018 at the Sheraton Seattle Hotel and will be followed by a press conference* at 4:00 PM Pacific Time to highlight new AlloSure data.
The symposium’s agenda is as follows:
- Evolving role of molecular biomarkers in Banff criteria for diagnosis of acute antibody mediated rejection (ABMR) – Mark Haas, M.D., Ph.D., Professor of Pathology; Senior Attending Pathologist – Cedars Sinai Comprehensive Transplant Center
- Introduction to AlloSure – donor-derived cell-free DNA (dd-cfDNA) – testing and implementation into clinical practice – Alexander Wiseman, M.D., Professor of Medicine; Medical Director, Renal and Transplant Programs – University of Colorado
- New approaches in ABMR diagnosis and assessing responses to treatment of ABMR – Stanley C. Jordan, M.D., Director, Division of Nephrology; Medical Director, Kidney Transplant Program; Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
- Clinical Experience using AlloSure for kidney transplant patients
a. Case Study – Aleksandra De Golovine, M.D., Medical Director of Renal and Pancreas Transplantation; Assistant Professor of Medicine, Division of Nephrology – Memorial Hermann Hospital
b. Case Study – Vinaya Rao, M.D., Professor, Medical Director, Kidney Transplant – Medical University of South Carolina
c. Case Study – Kalathil Sureshkumar, M.D., Department of Medicine, Division of Nephrology and Hypertension – Allegheny General Hospital
d. Case Study – Anup M. Patel, M.D. Transplant Clinical Director; Transplant Physician – Saint Barnabas Medical Center
Following the symposium, management CareDx will host a press conference* at 4:00 PM Pacific Time to highlight new AlloSure data. Daniel C. Brennan, M.D., Medical Director, Comprehensive Transplant Center – Johns Hopkins Medical Center will be available for a Q&A session.
“We look forward to participating at the 2018 American Transplant Conference and providing updates on the latest AlloSure data,” said Peter Maag, CareDx President and Chief Executive Officer. “Providing genomic information to the transplant clinic supports a paradigm shift and a new milestone in transplantation precision medicine, filling an unmet need in the care and surveillance of transplant patients.”
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
*This press conference is not part of the ATC official educational program
CONTACTS:
CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com
